BonusBio Group Ltd
Quick facts
Phase 3 pipeline
- MesenCure · Regenerative Medicine / Immunology
MesenCure is a mesenchymal stem cell-based therapy designed to promote tissue regeneration and reduce inflammation through paracrine signaling.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about BonusBio Group Ltd
What is BonusBio Group Ltd's pipeline?
BonusBio Group Ltd has 1 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include MesenCure.
Related
- Sector hub: All tracked pharma companies